Joseph Dagenbach, MD
Internal Medicine · Cincinnati, OHNPI 1205838109
Payments from drug & device makers
Across 158 payments — averaging $13.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$249
- Pfizer$199
- Amgen$195
- AbbVie$190
- AstraZeneca$146
- Novartis$123
- plus $977 from 22 others
What the payments were for
- Food & beverage$2,079100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 19 | $249 |
| Pfizer | 23 | $199 |
| Amgen | 15 | $195 |
| AbbVie(2 entities) | 19 | $190 |
| AstraZeneca | 6 | $146 |
| Novartis | 7 | $123 |
| Sanofi-aventis U.S. LLC | 9 | $120 |
| Lilly USA, LLC | 11 | $118 |
| Smith+Nephew | 7 | $99 |
| Amarin Pharma, Inc. | 6 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $73 |
| Teva Pharmaceuticals USA, Inc. | 4 | $55 |
| Boehringer Ingelheim | 3 | $50 |
| Paratek Pharmaceuticals, Inc. | 3 | $45 |
| Organogenesis Inc. | 2 | $40 |
| Johnson & Johnson | 3 | $38 |
| Astellas Pharma US Inc | 2 | $38 |
| Hikma Pharmaceuticals USA | 2 | $27 |
| GSK | 2 | $24 |
| Dexcom, Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Abbott | 1 | $22 |
| Gilead | 1 | $20 |
| Boston Scientific | 1 | $18 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Pulmonx Corporation | 1 | $13 |
| Daiichi Sankyo Inc. | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$2,079 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 182 | $196,903 |
| EliquisApixaban | 156 | $136,963 |
| OzempicSemaglutide | 121 | $133,824 |
| TrulicityDulaglutide | 62 | $66,582 |
| XareltoRivaroxaban | 59 | $59,195 |
| FarxigaDapagliflozin Propanediol | 44 | $47,405 |
| Repatha SureclickEvolocumab | 48 | $35,866 |
| MounjaroTirzepatide | 28 | $35,616 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $23,901 |
| VascepaIcosapent Ethyl | 31 | $20,640 |
| LinzessLinaclotide | 26 | $19,650 |
| Emgality PenGalcanezumab-Gnlm | 16 | $16,621 |
| MovantikNaloxegol Oxalate | 28 | $14,098 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $13,564 |
| Xtampza ErOxycodone Myristate | 12 | $12,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $50 | $203,693194 claims |
| PfizerEliquis | $199 | $136,963156 claims |
| Novo NordiskOzempic | $249 | $133,824121 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $118 | $102,19790 claims |
| Johnson & JohnsonXarelto | $38 | $59,19559 claims |
| AstraZenecaFarxiga, Symbicort | $146 | $50,26357 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $24 | $30,58744 claims |
| AbbVieLinzess | $190 | $19,65026 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $5,45221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.
Other internal medicine in Cincinnati
- Antoinette PragalosCincinnati$27.8M
- Charles EgerCincinnati$8.7M
- Douglas LoganCincinnati$4.7M
- Leela VrishabhendraCincinnati$3.4M
- Traci TurnerCincinnati$645K
- Vincent MartinCincinnati$398K
- Lisa LarkinCincinnati$276K
- Mark EckmanCincinnati$255K
- Kay JohnsonCincinnati$184K
- Steven FolkerthBeavercreek$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.